

**Arsenic Trioxide Phebra included in the framework agreement for NHS National  
Pharmaceuticals Transition 2019\_1. Offer reference number: CM/PHG/17/5547**

FARNBOROUGH, England, September 25<sup>th</sup> 2019: Flexipharm Austrading the UK specialty pharmaceutical company focused on supplying the NHS with Better. Critical Care Medicines, today announced that its product Arsenic Trioxide Phebra 1mg/ml concentrate for solution for infusion vials, has been successful in its submission to supply NHS England under the above framework agreement which starts on October 1 2019.

Arsenic Trioxide Phebra is a glass vial presentation of arsenic trioxide 1mg/ml concentrate solution for infusion, a NICE-recommended treatment (in combination with all-trans retinoic acid) for newly diagnosed low-intermediate risk and relapsed acute promyelocytic leukaemia or APML<sup>1,2</sup>.

Arsenic Trioxide Phebra 1mg/ml concentrate for solution for infusion is available exclusively from Mawdsleys the specialist hospital wholesaler and can be ordered from Mawdsleys by phone, fax, online, EDI or email to [customer.services@mawdsleys.co.uk](mailto:customer.services@mawdsleys.co.uk).

Product details are as follows;

Product Name	<b>Arsenic Trioxide Phebra 1mg/ml concentrate for solution for infusion</b>
Manufacturer	<b>Flexipharm Austrading Limited</b>
Pack Size	<b>One pack is 10 x 10ml vials</b>
PIP Code	<b>1231034</b>
EAN Number	<b>5060653040001</b>

Product details can also be found on pharmaQC under the NPC code DLK047

Further details on Flexipharm Austrading Limited, including how to contact us in regard to any additional supply enquiries, technical information enquiries and Adverse Event reporting can be found at [www.flexipharmaustrading.com](http://www.flexipharmaustrading.com)

### **About Flexipharm Austrading**

Flexipharm Austrading's vision is to become a UK-based specialty pharmaceutical company that is genuinely respected and trusted by NHS hospitals. It was set up in 2018 by Michael Clark, an experienced specialty pharmaceutical company founder and board director.

Flexipharm Austrading has a singular focus on established molecules embedded in hospital use where there are concerns around security of ongoing supply; where the current presentation is not optimal

for the needs of the NHS staff; and where the current presentations can contribute to medication errors.

Flexipharm Austrading has a deep understanding of the conditions where its medicines are used and builds enduring meaningful dialogue with the NHS staff involved in using these medicines. It has an exclusive distribution agreement with Phebra Pty Ltd, an Australian pharmaceutical company that develops and manufactures injectable pharmaceutical products. Flexipharm Austrading will be launching several products from the Phebra portfolio in the UK in 2019 and 2020.

For more information please contact:

**Flexipharm Austrading**

Michael Clark

Tel: +44 (0) 1628 290 433 [inquiries@flexipharmaustrading.com](mailto:inquiries@flexipharmaustrading.com)

References

1. <https://www.nice.org.uk/guidance/ta526/resources/resource-impact-report-pdf-4850877421>
2. <https://www.medicines.org.uk/emc/product/10278>  
Ampoule price of £2920.00 for a pack of 10 x 10ml ampoules,  
<https://bnf.nice.org.uk/medicinal-forms/arsenic-trioxide.html> accessed 17/05/2019. Arsenic Trioxide Phebra NHS price is £2700.00 for a pack of 10 x 10ml vials